VKTX Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 33.55%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Amgen, Inc.'s return on equity of 95.55%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 142.13%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that Viking Therapeutics, Inc. has higher upside potential than Amgen, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Amgen, Inc..

Viking Therapeutics, Inc. has a beta of 0.649, which suggesting that the stock is 35.072% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Axsome Therapeutics, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of -27.62%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 142.13%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $181.31 which suggests that it could grow by 21.41%. Given that Viking Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Viking Therapeutics, Inc. has a beta of 0.649, which suggesting that the stock is 35.072% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.416%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 12.98x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 31.72%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Eli Lilly & Co.'s return on equity of 106.26%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 142.13%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Viking Therapeutics, Inc. has a beta of 0.649, which suggesting that the stock is 35.072% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 21.32%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Pfizer Inc.'s return on equity of 10.84%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 142.13%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Viking Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Pfizer Inc..

Viking Therapeutics, Inc. has a beta of 0.649, which suggesting that the stock is 35.072% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.